Shares of Seelos Therapeutics, Inc. (NASDAQ:SEEL) have been given an average recommendation of “Buy” by the six analysts that are presently covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $8.92.
A number of research analysts have commented on SEEL shares. Roth Capital upgraded shares of Seelos Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $2.50 to $8.00 in a research note on Monday, September 27th. Zacks Investment Research upgraded shares of Seelos Therapeutics from a “hold” rating to a “buy” rating and set a $2.50 price target for the company in a research note on Wednesday. Guggenheim started coverage on shares of Seelos Therapeutics in a research note on Thursday, July 1st. They set a “buy” rating and a $8.00 price target for the company. Finally, B. Riley cut their price target on shares of Seelos Therapeutics from $15.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, August 18th.
A number of hedge funds have recently bought and sold shares of SEEL. Victory Capital Management Inc. bought a new position in Seelos Therapeutics in the 1st quarter worth approximately $54,000. Commonwealth Equity Services LLC acquired a new stake in Seelos Therapeutics during the 1st quarter worth $92,000. BlackRock Inc. grew its holdings in Seelos Therapeutics by 115.1% during the 1st quarter. BlackRock Inc. now owns 1,193,063 shares of the company’s stock worth $5,953,000 after acquiring an additional 638,363 shares during the period. HighTower Advisors LLC grew its holdings in Seelos Therapeutics by 9.2% during the 1st quarter. HighTower Advisors LLC now owns 24,660 shares of the company’s stock worth $123,000 after acquiring an additional 2,075 shares during the period. Finally, UBS Group AG grew its holdings in Seelos Therapeutics by 22,020.5% during the 1st quarter. UBS Group AG now owns 8,627 shares of the company’s stock worth $43,000 after acquiring an additional 8,588 shares during the period. Hedge funds and other institutional investors own 39.90% of the company’s stock.
Seelos Therapeutics (NASDAQ:SEEL) last released its earnings results on Monday, August 9th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. As a group, analysts forecast that Seelos Therapeutics will post -0.57 earnings per share for the current fiscal year.
About Seelos Therapeutics
Seelos Therapeutics, Inc is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm’s portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder �or Post-Traumatic Stress Disorder, �amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson’s disease, other psychiatric and movement disorders plus orphan diseases.
See Also: What is intrinsic value?
Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.